Gout News

  • FDA Repays Industry by Rushing Risky Drugs to Market As pharma companies underwrite three-fourths of the FDA’s budget for scientific reviews, the agency is increasingly fast-tracking expensive drugs with significant side effects and unproven health benefits.
  • Public Citizen Calls on FDA to Pull Gout Drug Due to CV Risk The nonprofit advocacy group says there is 'overwhelming evidence that the serious cardiovascular harms of febuxostat outweigh any purported clinical benefit,' citing CARES postmarket data.

Gout Perspective

  • Recurrent Skin Infections in a Teen: How Would You Manage? It's an extremely vexing problem for families: recurrent skin infections in a teen athlete.
  • The Lean Antibiotic Mantra Antibiotics -- while focusing on the right drug, the right dose, and the right duration, most important is to make the right diagnosis. Sometimes you may not even need the antibiotic.